Bayer: applies to EU for finerenone
(CercleFinance.com) - Bayer announces that the European Medicines Agency has received a marketing authorization application for finerenone in the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥40%.
A Phase III study showed that this drug, a selective non-steroidal mineralocorticoid receptor antagonist, delivers cardiovascular benefits.
Already marketed under the names Kerendia and Firialta, finerenone is approved in over 90 countries for the treatment of diabetic nephropathy.
Bayer has also submitted applications in the USA and China, with further submissions to follow.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
A Phase III study showed that this drug, a selective non-steroidal mineralocorticoid receptor antagonist, delivers cardiovascular benefits.
Already marketed under the names Kerendia and Firialta, finerenone is approved in over 90 countries for the treatment of diabetic nephropathy.
Bayer has also submitted applications in the USA and China, with further submissions to follow.
Copyright (c) 2025 CercleFinance.com. All rights reserved.